Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Intervalo de año de publicación
1.
Einstein (Sao Paulo) ; 18: eAO4995, 2020.
Artículo en Inglés, Portugués | MEDLINE | ID: mdl-32074221

RESUMEN

OBJECTIVE: To describe antiretroviral treatment regimens prescribed and their compliance with the Clinical Protocol and Therapy Guidelines of the Ministry of Health for the management of HIV infection. METHODS: Observational and descriptive study. Secondary data of the state of Paraná (Brazil) on drugs, treatment regimens, lines of treatment and number of individuals on treatment, from January to June 2018, were accessed at the Antiretroviral Agents Logistic Control System. Combinations of antiretroviral drugs (treatment regimens) were compared according to the current Clinical Protocol and Therapy Guidelines and non-compliances were classified and quantified. RESULTS: In Paraná, 35,127 individuals with HIV were treated with 253 different treatment regimens. Of the prescribed regimens, 19.1% were first-line, 27.4% second-line and 48.5% third-line. Among non-compliances, the most prevalent were absence of association of protease inhibitors and ritonavir (42.8%), low efficacy triple therapy (36.9%), double therapy (26.1%), monotherapy (20.3%), and triple therapy of nucleoside analog reverse transcriptase inhibitors (17.1%). CONCLUSION: Most individuals receiving HIV treatment in the state of Paraná are on treatment regimens established in the current Clinical Protocol and Therapy Guidelines, which contributes to successful therapy. However, associations not provided by the current Clinical Protocol and Therapy Guidelines were identified in the initial treatment lines, which could lead to ineffectiveness, virologic failure and viral resistance.


Asunto(s)
Antirretrovirales/administración & dosificación , Protocolos Clínicos/normas , Adhesión a Directriz/normas , Cumplimiento de la Medicación , Fármacos Anti-VIH/administración & dosificación , Fármacos Anti-VIH/uso terapéutico , Antirretrovirales/uso terapéutico , Brasil , Quimioterapia Combinada/normas , Quimioterapia Combinada/estadística & datos numéricos , Adhesión a Directriz/estadística & datos numéricos , Infecciones por VIH/tratamiento farmacológico , Humanos , Cumplimiento de la Medicación/estadística & datos numéricos
2.
Einstein (São Paulo, Online) ; 18: eAO4995, 2020. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1090037

RESUMEN

ABSTRACT Objective To describe antiretroviral treatment regimens prescribed and their compliance with the Clinical Protocol and Therapy Guidelines of the Ministry of Health for the management of HIV infection. Methods Observational and descriptive study. Secondary data of the state of Paraná (Brazil) on drugs, treatment regimens, lines of treatment and number of individuals on treatment, from January to June 2018, were accessed at the Antiretroviral Agents Logistic Control System. Combinations of antiretroviral drugs (treatment regimens) were compared according to the current Clinical Protocol and Therapy Guidelines and non-compliances were classified and quantified. Results In Paraná, 35,127 individuals with HIV were treated with 253 different treatment regimens. Of the prescribed regimens, 19.1% were first-line, 27.4% second-line and 48.5% third-line. Among non-compliances, the most prevalent were absence of association of protease inhibitors and ritonavir (42.8%), low efficacy triple therapy (36.9%), double therapy (26.1%), monotherapy (20.3%), and triple therapy of nucleoside analog reverse transcriptase inhibitors (17.1%). Conclusion Most individuals receiving HIV treatment in the state of Paraná are on treatment regimens established in the current Clinical Protocol and Therapy Guidelines, which contributes to successful therapy. However, associations not provided by the current Clinical Protocol and Therapy Guidelines were identified in the initial treatment lines, which could lead to ineffectiveness, virologic failure and viral resistance.


RESUMO Objetivo Descrever esquemas terapêuticos de antirretrovirais prescritos e sua conformidade com o Protocolo Clínico e Diretrizes Terapêuticas, do Ministério da Saúde, para manejo da infecção pelo HIV. Métodos Estudo observacional e descritivo. Os dados do estado do Paraná sobre medicamentos que compõem os esquemas terapêuticos, linhas de tratamento e número de pessoas em uso destes foram acessados no Sistema de Controle Logístico de Medicamentos Antirretrovirais no período de janeiro a junho de 2018. As combinações de antirretrovirais (esquemas terapêuticos) foram comparadas conforme o Protocolo Clínico e Diretrizes Terapêuticas vigente, e as inconformidades foram categorizadas e quantificadas. Resultados No Paraná, 35.127 pessoas com HIV foram tratadas com 253 esquemas terapêuticos distintos. Dentre os esquemas prescritos, 19,1% eram de primeira linha, 27,4% de segunda linha e 48,5% de terceira linha. Nas inconformidades, predominaram a não associação entre inibidores da protease e ritonavir (42,8%), terapia tripla de baixa eficiência (36,9%), terapia dupla (26,1%), monoterapia (20,3%) e terapia tripla de inibidores da transcriptase reversa análogos de nucleosídeos (17,1%). Conclusão Maior parte das pessoas em tratamento do HIV no Paraná utilizam esquemas terapêuticos previstos no Protocolo Clínico e Diretrizes Terapêuticas vigente, o que contribui para o sucesso terapêutico. Entretanto, associações não previstas foram identificadas nas linhas de tratamento iniciais, podendo ocasionar inefetividade, falha virológica e resistência viral.


Asunto(s)
Humanos , Protocolos Clínicos/normas , Adhesión a Directriz/normas , Antirretrovirales/administración & dosificación , Brasil , Infecciones por VIH/tratamiento farmacológico , Fármacos Anti-VIH/administración & dosificación , Fármacos Anti-VIH/uso terapéutico , Adhesión a Directriz/estadística & datos numéricos , Antirretrovirales/uso terapéutico , Quimioterapia Combinada/normas , Quimioterapia Combinada/estadística & datos numéricos , Cumplimiento de la Medicación/estadística & datos numéricos
3.
Mil Med ; 184(Suppl 1): 644-651, 2019 03 01.
Artículo en Inglés | MEDLINE | ID: mdl-30901461

RESUMEN

Ionizing radiation exposure is a major concern for active military service members, as well as civilian population. Considering that the exposure is not predictable, it is imperative that strategies to counteract radiation damage must be discovered. Recent in vitro studies performed in our laboratory demonstrated that the vitamin E analog gamma-tocotrienol (GT3) in combination with cholesterol-lowering drugs (Statins), synergistically induced endothelial thrombomodulin, an anticoagulant with radio-protective efficacy. It was hypothesized that the combination of treatment with both GT3 along with Statins would provide better radiation protection in vivo than each drug individually. CD2F1 mice were injected subcutaneously with either vehicle or single dose of GT3 (200 mg/kg body weight) 24 hours before irradiation followed by oral or subcutaneous administration of various doses of simvastatin (25, 50, and 100 mg/kg body weight) before exposure to lethal doses (11.5 and 12 Gy) of Cobalt-60 (60Co) gamma-irradiation. The combined treatment group exhibited enhanced radiation lethality protection substantially, accelerated white blood cell recovery, and augmented restoration of bone marrow cellularity when compared to the animals treated with either drug exclusively. This information clearly suggests that combined treatment could be used as a safeguard for military personnel from exposure to harmful ionizing radiation.


Asunto(s)
Cromanos/farmacología , Quimioterapia Combinada/normas , Simvastatina/farmacología , Vitamina E/análogos & derivados , Animales , Cromanos/uso terapéutico , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada/métodos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Masculino , Ratones , Exposición Profesional/efectos adversos , Radiación Ionizante , Simvastatina/uso terapéutico , Análisis de Supervivencia , Vitamina E/farmacología , Vitamina E/uso terapéutico
4.
Rev. cuba. anestesiol. reanim ; 16(2): 52-62, may.-ago. 2017.
Artículo en Español | LILACS, CUMED | ID: biblio-960308

RESUMEN

La sedoanalgesia en pacientes bajo ventilación mecánica artificial se recomienda para lograr una mejor satisfacción del paciente y prevenir complicaciones. El objetivo de este trabajo fue realizar una revisión bibliográfica sobre la acción sedoanalgésica de la combinación de midazolam-morfina comparado con midazolam-ketamina en pacientes críticos tratados con ventilación mecánica artificial. Se realizó una búsqueda manual y digital en diferentes bases de datos como Scielo, IBECS, MEDLINE, Google Scholar, Cochrane y Wh, con los descriptores en inglés siguientes: sedation, midazolam-ketamine, midazolam-morfina AND mechanical ventilation AND crtical illness [MeSH Terms]. Se encontró un total de 60 artículos, todos realizados en seres humanos, 32 en los últimos 5 años, pero solo 16 a texto completo. De ellos, 7 eran revisiones sistemáticas sobre el tema y solo 4 ensayos clínicos. Ninguno utilizó la asociación midazolam-ketamina para la sedación. En la revisión realizada no se encontró ningún artículo que informara sobre las ventajas de la asociación midazolam-ketamina en la sedación del paciente crítico ventilado mecánicamente, lo que le confiere novedad a la investigación(AU)


The sedoanalgesia is recommended for patients under artificial mechanical ventilation in order to achieve better patient satisfaction and to prevent complications. The objective of this work was to carry out a literature review about the sedoanalgesic effect to the combination of midazolam-morphine compared with comidazolam-ketamine in critically ill patients treated with artificial mechanical ventilation. A manual and digital search was carried out in different databases such as Scielo, IBECS, MEDLINE, Google Scholar, Cochrane, and Wh, using the following descriptors in English: sedation, midazolam-ketamine, midazolam-morphine, AND mechanical ventilation AND critical illness (MeSH terms). We found 60 articles, all of which reported human-related cases, 32 in the last 5 years, but only 16 at full text. Out of these, seven were systematic reviews about the subject and only four, clinical trials. We did not find any articles in the review that reported about the advantages of the association midazolam-ketamine in sedation of mechanically ventilated critically ill patients, a fact that confers novelty to the investigation.


Asunto(s)
Humanos , Respiración Artificial/métodos , Midazolam/uso terapéutico , Cuidados Críticos/métodos , Ketamina/uso terapéutico , Quimioterapia Combinada/normas , Sedación Profunda/métodos
5.
Liver Int ; 34 Suppl 1: 13-7, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24373073

RESUMEN

The standard of care (SOC) for hepatitis C virus (HCV) genotype 2 is pegylated interferon (PEG-IFN) plus ribavirin (RBV). Even though most patients can be cured with this therapy after 24 weeks, tailoring treatment can improve its safety and efficacy in special populations. Thus, shortening treatment together with a weight-based RBV dosing approach has been considered satisfactory in patients with positive predictors of response. With the development of the direct antiviral agents (DAAs), shorter, better tolerated and more efficient treatments for HCV genotype 2 will become available, including interferon-free regimens. Until these new treatments are released, the decision to treat patients with HCV genotype 2 with currently approved drugs or to wait for future options must be made, taking into account the stage of fibrosis.


Asunto(s)
Antivirales/uso terapéutico , Quimioterapia Combinada/métodos , Hepacivirus/efectos de los fármacos , Hepatitis C/tratamiento farmacológico , Interferón-alfa/uso terapéutico , Polietilenglicoles/uso terapéutico , Ribavirina/uso terapéutico , Algoritmos , Antivirales/efectos adversos , Quimioterapia Combinada/normas , Genotipo , Hepacivirus/genética , Humanos , Proteínas Recombinantes/uso terapéutico , Nivel de Atención/tendencias , Factores de Tiempo , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA